- Home
- COGT vs REPX Comparison
COGT vs REPX Comparison
Compare COGT & REPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- REPX
- Stock Information
- Founded
- COGT 2014
- REPX 2016
- Country
- COGT United States
- REPX United States
- Employees
- COGT N/A
- REPX N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- REPX Oil & Gas Production
- Sector
- COGT Health Care
- REPX Energy
- Exchange
- COGT Nasdaq
- REPX Nasdaq
- Market Cap
- COGT 545.3M
- REPX 568.6M
- IPO Year
- COGT 2018
- REPX N/A
- Fundamental
- Price
- COGT $4.81
- REPX $26.59
- Analyst Decision
- COGT Buy
- REPX Strong Buy
- Analyst Count
- COGT 7
- REPX 1
- Target Price
- COGT $14.00
- REPX $47.00
- AVG Volume (30 Days)
- COGT 1.3M
- REPX 85.7K
- Earning Date
- COGT 05-06-2025
- REPX 05-07-2025
- Dividend Yield
- COGT N/A
- REPX 5.73%
- EPS Growth
- COGT N/A
- REPX N/A
- EPS
- COGT N/A
- REPX 4.67
- Revenue
- COGT N/A
- REPX $412,894,000.00
- Revenue This Year
- COGT N/A
- REPX $2.86
- Revenue Next Year
- COGT N/A
- REPX $4.05
- P/E Ratio
- COGT N/A
- REPX $5.68
- Revenue Growth
- COGT N/A
- REPX 1.25
- 52 Week Low
- COGT $3.72
- REPX $21.98
- 52 Week High
- COGT $12.61
- REPX $37.55
- Technical
- Relative Strength Index (RSI)
- COGT 44.64
- REPX 50.27
- Support Level
- COGT $4.55
- REPX $24.31
- Resistance Level
- COGT $5.89
- REPX $26.03
- Average True Range (ATR)
- COGT 0.38
- REPX 1.02
- MACD
- COGT 0.09
- REPX 0.26
- Stochastic Oscillator
- COGT 34.55
- REPX 68.58
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.